Recurrence of Primary Acquired Melanosis and Conjunctival Intraepithelial Neoplasia.

Pub Date : 2023-02-01 DOI:10.1159/000526985

Karin Svedberg

{"title":"Recurrence of Primary Acquired Melanosis and Conjunctival Intraepithelial Neoplasia.","authors":"Karin Svedberg","doi":"10.1159/000526985","DOIUrl":null,"url":null,"abstract":"Introduction: The aim of this study was to investigate the frequency of recurrences, time to recurrence, and which patients had a recurrence after treatment of conjunctival intraepithelial neoplasia (CIN), carcinoma in situ, and primary acquired melanosis (PAM) with atypia.Methods: A retrospective chart review of all patients included in the follow-up program after completion of treatment for CIN or PAM with atypia on October 18, 2021, at the Department of Ophthalmology, Sahlgrenska University Hospital, was conducted.Results: There were five recurrences (5/31, 17%) in the group with CIN or carcinoma in situ: two for patients with CIN grade II and three for individuals with carcinoma in situ. Time to diagnosis of recurrence ranged from 6 to 288 months. No recurrence was diagnosed for the 26 patients followed after treatment for PAM with atypia.Conclusion: With the strategy of radical treatment for CIN and PAM with atypia, whenever possible, subsequent follow-up can probably be ceased after 10 years if the patient is not immunocompromised. For completely excised PAM with atypia grade I, there is most likely no need for further clinical controls.","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/27/fb/oop-0008-0236.PMC10013497.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000526985","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

Introduction: The aim of this study was to investigate the frequency of recurrences, time to recurrence, and which patients had a recurrence after treatment of conjunctival intraepithelial neoplasia (CIN), carcinoma in situ, and primary acquired melanosis (PAM) with atypia.

Methods: A retrospective chart review of all patients included in the follow-up program after completion of treatment for CIN or PAM with atypia on October 18, 2021, at the Department of Ophthalmology, Sahlgrenska University Hospital, was conducted.

Results: There were five recurrences (5/31, 17%) in the group with CIN or carcinoma in situ: two for patients with CIN grade II and three for individuals with carcinoma in situ. Time to diagnosis of recurrence ranged from 6 to 288 months. No recurrence was diagnosed for the 26 patients followed after treatment for PAM with atypia.

Conclusion: With the strategy of radical treatment for CIN and PAM with atypia, whenever possible, subsequent follow-up can probably be ceased after 10 years if the patient is not immunocompromised. For completely excised PAM with atypia grade I, there is most likely no need for further clinical controls.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

原发性获得性黑色素瘤和结膜上皮内瘤变的复发。

简介:本研究旨在探讨结膜上皮内瘤变(CIN)、原位癌(carcinoma in situ)和原发性获得性黑色素瘤(PAM)伴异型性治疗后的复发频率、复发时间和复发患者。方法:回顾性分析所有于2021年10月18日在Sahlgrenska大学医院眼科完成非典型性CIN或PAM治疗后纳入随访计划的患者。结果:CIN或原位癌组有5例复发(5/ 31,17 %)，其中CIN II级2例，原位癌3例。到诊断复发的时间为6 ~ 288个月。26例非典型性PAM治疗后无复发。结论:对于异型性CIN和PAM采取根治性治疗策略，只要有可能，如果患者没有免疫功能低下，10年后可以停止后续随访。对于完全切除的非典型性I级PAM，很可能不需要进一步的临床对照。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助